Stockscreener 앱 받기
10.55
5.03%
0.5023
전일 마감가:
$10.05
열려 있는:
$10.16
하루 거래량:
592.90K
Relative Volume:
0.61
시가총액:
$623.96M
수익:
$106.47M
순이익/손실:
$82.89M
주가수익비율:
7.065
EPS:
1.4936
순현금흐름:
$-2.43M
1주 성능:
+6.62%
1개월 성능:
+12.29%
6개월 성능:
+4.82%
1년 성능:
+31.95%
1일 변동 폭
$10.16
$10.66
1주일 범위
$9.475
$10.66
52주 변동 폭
$7.16
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
명칭
Zevra Therapeutics Inc
전화
(888) 958-1253
주소
101 FEDERAL STREET, BOSTON
Compare ZVRA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
10.55 | 594.10M | 106.47M | 82.89M | -2.43M | 1.4936 |
VRTX
Vertex Pharmaceuticals Inc
|
421.71 | 109.34B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
702.06 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
797.87 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
299.37 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
294.92 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 개시 | BTIG Research | Buy |
| 2025-07-02 | 개시 | H.C. Wainwright | Buy |
| 2025-01-08 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-10-07 | 개시 | Guggenheim | Buy |
| 2024-09-24 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-24 | 재확인 | Maxim Group | Buy |
| 2024-04-02 | 재확인 | Maxim Group | Buy |
| 2024-03-12 | 개시 | William Blair | Outperform |
| 2023-03-17 | 개시 | Maxim Group | Buy |
모두보기
Zevra Therapeutics Inc 주식(ZVRA)의 최신 뉴스
MSN Money - MSN
ZVRA Stock Price, Quote & Chart | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill
Zevra Therapeutics (ZVRA) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
ZVRA Technical Analysis | Trend, Signals & Chart Patterns | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill
ZVRA stock soars on upbeat Q4 results, optimism for EMA approval of Niemann-Pick disease treatment - MSN
Zevra Therapeutics announces CFO transition - MSN
Discipline and Rules-Based Execution in ZVRA Response - Stock Traders Daily
Zevra Therapeutics rises amid takeover speculation - MSN
Zevra Therapeutics gains amid takeover speculation - MSN
Zevra Therapeutics schedules first quarter 2026 results release and webcast for May 6 - Traders Union
Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call - The Globe and Mail
Zevra to release first-quarter results after market close May 6 - Stock Titan
ZEVRA THERAPEUTICS, INC. ($ZVRA) CEO 2025 Pay Revealed - Quiver Quantitative
Zevra Therapeutics (ZVRA) Stock: End of Year (+0.52%) 2026-04-20Expert Verified Trades - Xã Vĩnh Công
Board changes and rare-disease growth at Zevra (ZVRA) highlight 2026 proxy - Stock Titan
Zevra Therapeutics to Engage Neurology Community at AANAM 2026 Booth in Chicago - Traders Union
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Behavioral Patterns of ZVRA and Institutional Flows - Stock Traders Daily
Short Squeeze: Will Zevra Therapeutics Inc benefit from geopolitical trendsMarket Performance Summary & Free Verified High Yield Trade Plans - baoquankhu1.vn
Moving Averages: Can Zevra Therapeutics Inc maintain sales growth2026 Support & Resistance & AI Enhanced Execution Alerts - baoquankhu1.vn
Zevra Therapeutics (NASDAQ:ZVRA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Is Zevra Therapeutics (ZVRA) Stock Safe to Buy Now | Price at $9.48, Down 2.37%High Attention Stocks - Cổng thông tin điện tử Tỉnh Sơn La
ZVRA SEC FilingsZevra Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Published on: 2026-04-10 05:39:10 - baoquankhu1.vn
Returns Recap: Should I add Zevra Therapeutics Inc stock to my portfolioMarket Performance Report & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Stratos Wealth Partners LTD. Boosts Stake in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics (NASDAQ: ZVRA) posts $106.5M 2025 revenue; proxy items - Stock Titan
Zevra shares jump after selling SDX portfolio for $50M - MSN
(ZVRA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
JPMorgan Chase & Co. Has $4.18 Million Stock Holdings in Zevra Therapeutics, Inc. $ZVRA - marketbeat.com
Zevra Therapeutics Inc (1GDA.HM) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
ZVRA PE Ratio & Valuation, Is ZVRA Overvalued - Intellectia AI
ZVRA Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
Hennion & Walsh Asset Management Inc. Invests $1.25 Million in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics Earnings Call Signals Profitable Turn - The Globe and Mail
Zevra Therapeutics Inc (1GDA.HM) interactive stock chart - Yahoo Finance UK
Sentiment Recap: Will Zevra Therapeutics Inc benefit from geopolitical trendsTrade Entry Report & Community Supported Trade Ideas - baoquankhu1.vn
ZVRA Stock Analysis: Zevra Therapeutics Inc. biotech rises 2.36 percent to 9.54 - Cổng thông tin điện tử tỉnh Tây Ninh
Nio, Zevra Therapeutics, Vertex Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
Dividend Watch: Is Zevra Therapeutics Inc forming bullish engulfing patternsWeekly Risk Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
Zevra Therapeutics Inc (ZVRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.94%
1.54%
자본화:
|
볼륨(24시간):